The Amplatzer steerable delivery sheath works with the Amplatzer Amulet left atrial appendage (LAA) occluder to treat people with AFib who are at risk of ischemic stroke
According to a news release, the Amulet with dual-seal technology offers immediate and complete closure of the LAA. It received FDA approval to reduce stroke risk for AFib patients in August 2021. The company said that, unlike competitive devices, the Amplatzer Amulet reduces the risk of stroke without requiring blood-thinning medication following the procedure.
The Amplatzer steerable delivery sheath includes bi-directional steering and an auto-lock function to offer confidence that the sheath will remain in its desired position. Abbott Park, Illinois-based Abbott said the delivery system also includes a valve designed to stabilize blood flow and minimize blood loss during the procedure.
“The Amulet LAA Occluder and Amplatzer Steerable Delivery Sheath are examples of Abbott’s commitment to helping people with structural heart diseases live their best lives, and we remain committed to the continued innovation of our technology for the benefit of physicians and patients worldwide,” SVP of Abbott’s structural heart business Michael Dale said in the release. “Abbott is focused on advancing technology for LAA occlusion devices as well as how they are delivered to optimize the physician experience and improve outcomes for patients.”
